Suppr超能文献

通过细胞角蛋白20基因和蛋白表达鉴定结直肠癌患者淋巴结阴性中的隐匿肿瘤细胞

Identification of occult tumor cells in node negative lymph nodes of colorectal cancer patients by cytokeratin 20 gene and protein expression.

作者信息

Lassmann S, Bauer M, Rosenberg R, Nekarda H, Soong R, Rüger R, Höfler H, Werner M

机构信息

Pathologisches Institut, Universitätsklinikum Freiburg, Albertstrasse 19, 79104 Freiburg, Germany.

出版信息

Int J Colorectal Dis. 2004 Mar;19(2):87-94. doi: 10.1007/s00384-003-0530-z. Epub 2003 Sep 10.

Abstract

BACKGROUND AND AIMS

Evaluation of cytokeratin 20 (CK20) specific quantitative reverse transcriptase polymerase chain reaction (QRT-PCR) and immunohistochemistry (IHC) for detection of occult tumor cells in lymph nodes of 72 patients with colorectal carcinoma (UICC stage I and II).

METHODS

Serial sections of formalin-fixed, paraffin-embedded lymph nodes (mean 14.3/case) were used for microdissection, RNA isolation and QRT-PCR and for CK20 IHC using routine protocols. Results of QRT-PCR and IHC were compared and correlated to the CK20 expression pattern of the primary tumors and clinical follow-up.

RESULTS

IHC revealed CK20-positive tumor cells in lymph nodes of 14.5% (10/69) and 0% (0/3) cases with a CK20-positive and CK20-negative primary tumor, respectively. CK20 mRNA was detected in the lymph nodes of 36.8% (7/19) cases by QRT-PCR with all 7 cases also expressing CK20 mRNA in the primary tumor. CK20 mRNA (QRT-PCR) and protein (IHC) detection in serial sections did not agree in 25% (5/20) of cases. A trend was seen towards a worse disease course for patients with CK20-positive lymph nodes by IHC (incidence of recurrent disease) and QRT-PCR (disease-free survival, incidence of recurrent disease).

CONCLUSION

CK20-specific IHC and QRT-PCR are supportive tools to conventional histology for detection of occult tumor cells in archival tissues, with the restriction that a laborious QRT-PCR procedure is necessary to achieve appropriate specificity. A prognostic value of CK20 IHC or QRT-PCR for stratification of UICC stage I and II patients into those likely to develop recurrent disease was not evident.

摘要

背景与目的

评估细胞角蛋白20(CK20)特异性定量逆转录聚合酶链反应(QRT-PCR)和免疫组织化学(IHC)用于检测72例结直肠癌(UICC I期和II期)患者淋巴结中隐匿性肿瘤细胞的情况。

方法

使用福尔马林固定、石蜡包埋淋巴结的连续切片(平均每例14.3张)进行显微切割、RNA提取及QRT-PCR,并采用常规方案进行CK20免疫组织化学检测。将QRT-PCR和免疫组织化学的结果进行比较,并与原发肿瘤的CK20表达模式及临床随访情况相关联。

结果

免疫组织化学显示,CK20阳性原发肿瘤患者的淋巴结中,14.5%(10/69)的病例检测到CK20阳性肿瘤细胞;CK20阴性原发肿瘤患者的淋巴结中,0%(0/3)的病例检测到CK20阳性肿瘤细胞。通过QRT-PCR在36.8%(7/19)的病例淋巴结中检测到CK20 mRNA,所有7例原发肿瘤中也表达CK20 mRNA。连续切片中CK20 mRNA(QRT-PCR)和蛋白(免疫组织化学)检测结果在25%(5/20)的病例中不一致。免疫组织化学(复发疾病发生率)和QRT-PCR(无病生存期、复发疾病发生率)显示,CK20阳性淋巴结患者的疾病进程有变差的趋势。

结论

CK20特异性免疫组织化学和QRT-PCR是用于检测存档组织中隐匿性肿瘤细胞的传统组织学辅助工具,但限制在于需要繁琐的QRT-PCR程序以获得适当的特异性。CK20免疫组织化学或QRT-PCR对UICC I期和II期患者分层为可能发生复发疾病者的预后价值并不明显。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验